Mounjaro: The First Dual-Action GLP-1/GIP Treatment for Type 2 Diabetes

Mounjaro contains tirzepatide, the first dual GIP and GLP-1 receptor agonist. By activating both incretin receptors, it produces robust insulin secretion, glucagon suppression, and appetite reduction. The dual mechanism is believed to offer enhanced metabolic benefits compared to GLP-1-only agonists, including greater glucose lowering and substantially more weight loss.

Mounjaro (tirzepatide) is a first-in-class dual GIP/GLP-1 receptor agonist approved by the FDA in May 2022 for the treatment of type 2 diabetes in adults. Manufactured by Eli Lilly, it represents a new approach to incretin-based therapy by targeting two hormonal pathways instead of one. Mounjaro is injected once weekly using a pre-filled, single-dose pen (the KwikPen). While approved only for type 2 diabetes, Mounjaro gained significant attention for producing substantially more weight loss than any previously approved diabetes medication, leading to Eli Lilly developing Zepbound as a dedicated weight-management product with the same active ingredient.

The SURPASS clinical trial program was one of the largest and most comprehensive Phase 3 programs for a diabetes medication, enrolling over 7,500 participants across five pivotal trials. The results consistently showed that Mounjaro outperformed comparators across all endpoints. In the head-to-head SURPASS-2 trial against semaglutide 1 mg (Ozempic), Mounjaro demonstrated superior HbA1c reduction at all three doses and approximately double the weight loss. Across the program, Mounjaro 15 mg consistently achieved HbA1c reductions of 2.0-2.6%, bringing a majority of participants below the ADA treatment target of 7%. Weight loss was a consistent secondary finding, with 10-13 kg of weight reduction even in the diabetes population.

The SURPASS-2 trial provided the only randomized, head-to-head comparison between tirzepatide and semaglutide. Over 40 weeks in patients with type 2 diabetes, tirzepatide 5 mg, 10 mg, and 15 mg all produced superior HbA1c reductions compared to semaglutide 1 mg (-2.01%, -2.24%, and -2.46% vs -1.86%). Weight loss was also significantly greater: -7.6 kg, -9.3 kg, and -12.4 kg vs -6.2 kg. The rates of gastrointestinal side effects were similar between the two medications. This trial established tirzepatide as the most potent glucose-lowering injectable available.

Mounjaro is delivered via a single-dose, pre-filled KwikPen for each dose level. The pen has a hidden needle that patients do not see, which may reduce injection anxiety. To use: remove the cap, place the pen flat against the skin of the abdomen, thigh, or upper arm, unlock the pen by twisting the base, and press and hold the injection button for 10 seconds. A clicking sound indicates the injection is complete. Each pen contains a single dose and should be discarded after use. Rotate injection sites each week. Unused pens should be stored in the refrigerator; a pen can be kept at room temperature for up to 21 days.

Mounjaro is widely covered by commercial insurance plans for type 2 diabetes, often after trying metformin first. It is included on many formularies because its clinical data is strong and the diabetes indication is well-established. The list price is approximately $1,023 per month. Eli Lilly has offered a manufacturer savings card that can reduce the copay to as low as $25 per month for commercially insured patients. Medicare Part D coverage varies by plan. For patients prescribed Mounjaro off-label for weight loss (before Zepbound was available), insurance coverage was less reliable, and many denials occurred.